What question did this study set out to answer?

To evaluate the antihypertensive efficacy, safety, and temporal response profile of the beta-adrenergic receptor antagonist alprenolol compared with placebo.

January 12, 1969Acta Medica Scandinavica

ANTIHYPERTENSIVE THERAPY WITH ALPRENOLOL, Aβ‐ADRENERGIC RECEPTOR ANTAGONIST

View Full Paper

Ask AI

Bookmark

Why the study?

Does alprenolol reduce blood pressure in patients with hypertension?

Population

11 patients with hypertension

Comparison

Alprenolol administered in daily doses of 200 mg… vs Placebo administered for 12 weeks

Design

RCT, double-blind

Follow-up

12 weeks per preparation

Authors

GTGösta TibblinGeneral / Preventive / Lipids BÅBengt ÅbladAstraZeneca (Sweden)

Discussion

Member takes

Implication

Alprenolol offers effective BP control in hypertension; confirms beta-blocker efficacy in early placebo-controlled RCTs.

Key Points

To evaluate the antihypertensive efficacy, safety, and temporal response profile of the beta-adrenergic receptor antagonist alprenolol compared with placebo.
Double-blind cross-over trial in 11 patients with hypertension receiving 12 weeks of alprenolol and 12 weeks of placebo.
Alprenolol was administered in escalating daily doses: 200 mg for the first two weeks, 300 mg for the next two weeks, and 400 mg for the final eight weeks.
Alprenolol achieved statistically significant average reductions of approximately 20 mm Hg systolic and 10 mm Hg diastolic blood pressure relative to placebo across supine, sitting, and standing postures.
Therapeutic response exhibited two distinct timelines: rapid maximal reduction within two weeks in one subgroup, and progressive reduction reaching mean decreases of 36 mm Hg systolic and 23 mm Hg diastolic by week 12 in another subgroup.
One patient experienced effort angina attacks during higher-dose therapy linked to marked blood pressure reduction, with no other adverse effects or complications observed.

Structured PICO

Does alprenolol reduce blood pressure in patients with hypertension?

Population

11 patients with hypertension

Intervention

Alprenolol administered in daily doses of 200 mg for the first two weeks, 300 mg for the following two weeks, and 400 mg for the remaining eight weeks (total 12 weeks)

Comparator

Placebo administered for 12 weeks

Outcome

Reduction in systolic and diastolic blood pressure in supine, standing, and sitting positionssurrogate

Alprenolol effectively and significantly reduces both systolic and diastolic blood pressure in patients with hypertension.

Cite This Study

Tibblin et al. (1969) studied this question.

synapsesocial.com/papers/6a71b3335671bbf00bc2f0d2 https://doi.org/10.1111/j.0954-6820.1969.tb01502.x

View Full Paper

Ask AI

Bookmark

ANTIHYPERTENSIVE THERAPY WITH ALPRENOLOL, Aβ‐ADRENERGIC RECEPTOR ANTAGONIST

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

ANTIHYPERTENSIVE THERAPY WITH ALPRENOLOL, Aβ‐ADRENERGIC RECEPTOR ANTAGONIST

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider